NCT07651202

Brief Summary

This retrospective cross-sectional study evaluates the association between Helicobacter pylori infection and metabolic syndrome using health examination data from 5,218 adults at Nanjing First Hospital. Participants are divided into H. pylori-positive and negative groups based on urea breath test results. The primary outcome is metabolic syndrome prevalence (CDS 2020 criteria). Multivariable logistic regression will be used to assess the independent association, with subgroup analyses by age and sex.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5,218

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2024

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2025

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2026

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

June 11, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 16, 2026

Completed
Last Updated

June 16, 2026

Status Verified

April 1, 2026

Enrollment Period

1 year

First QC Date

June 11, 2026

Last Update Submit

June 11, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Prevalence of Metabolic Syndrome

    Metabolic syndrome is defined according to the Chinese Diabetes Society (CDS) 2020 criteria. Participants meeting three or more of the following five criteria are classified as having metabolic syndrome: (1) central obesity: waist circumference ≥90 cm in males or ≥85 cm in females; (2) hyperglycemia: fasting blood glucose ≥6.1 mmol/L or previously diagnosed diabetes on treatment; (3) hypertension: blood pressure ≥130/85 mmHg or previously diagnosed hypertension on treatment; (4) hypertriglyceridemia: fasting triglycerides ≥1.70 mmol/L; (5) low HDL-cholesterol: fasting HDL-cholesterol \<1.04 mmol/L.

    Baseline

Study Arms (2)

H. pylori Positive Group

Participants with positive 13C or 14C urea breath test result

Other: No intervention. This is an observational study.

H. pylori Negative Group

Participants with negative 13C or 14C urea breath test result

Other: No intervention. This is an observational study.

Interventions

No intervention. This is an observational study.

H. pylori Negative GroupH. pylori Positive Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adults (≥18 years) who completed annual health examinations at Nanjing First Hospital between May 1, 2024 and May 1, 2025, with complete data on H. pylori breath testing and metabolic syndrome components (waist circumference, blood pressure, fasting glucose, triglycerides, HDL-cholesterol). Pregnant/lactating women and those with severe organ dysfunction or malignancy were excluded.

You may qualify if:

  • Age ≥18 years
  • Completed annual health examination at Nanjing First Hospital Health Management Center between May 1, 2024 and May 1, 2025
  • Underwent 13C or 14C urea breath test for H. pylori status assessment
  • Complete data on the following measurements: height, weight, waist circumference, systolic blood pressure, diastolic blood pressure, fasting blood glucose, triglycerides, and high-density lipoprotein cholesterol
  • No missing data on key study variables

You may not qualify if:

  • Missing key data on H. pylori test results (13C or 14C urea breath test)
  • Missing any of the following primary metabolic indicators: waist circumference, blood pressure (systolic/diastolic), fasting blood glucose, triglycerides, or HDL-cholesterol
  • Pregnancy or lactation
  • History of severe liver dysfunction
  • History of severe kidney dysfunction
  • History of malignancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nanjing First Hospital, Nanjing Medical University

Nanjing, Jiangsu, China

Location

MeSH Terms

Conditions

Metabolic Syndrome

Condition Hierarchy (Ancestors)

Insulin ResistanceHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 11, 2026

First Posted

June 16, 2026

Study Start

May 1, 2024

Primary Completion

May 1, 2025

Study Completion

March 1, 2026

Last Updated

June 16, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations